The $2 billion fusion pharma purchase is a bet on new cancer treatments by a pharma company

Deal is AstraZeneca's second this month after it agreed to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio. The company also agreed last week to buy rare disease-resistant drug company Amoyt Pharma. Astra Zeneca is looking to boost its cancer treatments portfolio with Fusion Pharma.

Sandra Horsfield from Investec talks to Ian King about reaction to the Chancellor's budget. She also discusses AstraZeneca and Beazley. Investec: Reaction to the budget has been positive for the company. Ian King also discusses the impact of the budget on the UK economy.